The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the worldwide coronavirus disease 2019 (COVID-19) pandemic. Although the pathophysiology of SARS-CoV-2 infection is still being elucidated, the nicotinic cholinergic system may play a role. To evaluate the interaction of the SARS-CoV-2 virus with human nicotinic acetylcholine receptors (nAChRs), we assessed the in vitro interaction of the spike protein of the SARS-CoV-2 virus with various subunits of nAChRs. Electrophysiology recordings were conducted at α4β2, α3β4, α3α5β4, α4α6β2, and α7 neuronal nAChRs expressed in Xenopus oocytes. In cells expressing the α4β2 or α4α6β2 nAChRs, exposure to the 1 µg/mL Spike-RBD protein caused a marked reduction of the current amplitude; effects at the α3α5β4 receptor were equivocal and effects at the α3β4 and α7 receptors were absent. Overall, the spike protein of the SARS-CoV-2 virus can interact with select nAChRs, namely the α4β2 and/or α4α6β2 subtypes, likely at an allosteric binding site. The nAChR agonist varenicline has the potential to interact with Spike-RBD and form a complex that may interfere with spike function, although this effect appears to have been lost with the omicron mutation. These results help understand nAChR’s involvement with acute and long-term sequelae associated with COVID-19, especially within the central nervous system.

Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial

“…Some in vitro studies have found that the S protein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) inhibits certain nAChRs subtypes, such as α4β2 or α4α6β2. 22 , 23 In our study, after excluding subjects infected with COVID-19 (the mITT population), numerically greater improvements in EDS and STS at Week 4 were observed in both treatment groups compared with the ITT population. Additionally, in the mITT population analyzed per protocol, patients receiving OC-01 achieved a nominally greater reduction from baseline in EDS at Week 4 versus vehicle.…”

Efficient Expression in Leishmania tarentolae (LEXSY) of the Receptor-Binding Domain of the SARS-CoV-2 S-Protein and the Acetylcholine-Binding Protein from Lymnaea stagnalis

“…In addition, a large number of studies have recently appeared indicating the presence of other additional biological targets for recognition by the SARS-CoV-2 S-protein (and, in particular, its fragment–RBD), with the different nAChR subtypes being increasingly mentioned among them (see, for example, [ 59 ]). At the moment, the role of S-protein glycosylation in this interaction has not been studied at all.…”

Potential value of neuroimmunotherapy for COVID-19: efficacies and mechanisms of vagus nerve stimulation, electroacupuncture, and cholinergic drugs

“…nAChRs are a type of receptor found on the surface of many different types of cells, including immune cells. They are involved in a wide range of physiological processes, including the regulation of the immune system, and their activation can lead to inflammation and other harmful effects ( 81 ). Therefore, if the spike protein does indeed bind to these receptors, it could potentially have a number of effects on the human body, including exacerbating the inflammatory response associated with COVID-19.…”